Alliance Releases its FY 25 “Ask” for FDA Funding

EMBARGOED UNTIL MIDNIGHT ON APRIL 18, 2024

Alliance for a Stronger FDA Releases FY 25 Funding “Ask”

Alliance Proposes Increases to Meet Growing Demands on the FDA

April 18, 2024 | Silver Spring, MD – The Alliance for a Stronger FDA announced its FY 25 funding ask for FDA, calling for a budget authority (BA) appropriation of $3.896 billion for salaries and expenses (S&E). This is $214 million more than the President’s FY 25 budget request and $377 million more than the FY 24 funding level.

The Alliance’s request for FY 25 is consistent with its request from a year ago and reflects that the FDA’s funding needs have not diminished in the intervening time.

The Alliance believes that “the FDA’s growing mission requires a budget that grows. The American people are the beneficiaries of the continued investment in the agency and their needs are not met when the agency is underfunded.”

The Alliance further states:

FDA’s mission continues to grow, and its vital activities have become more complex and require greater sophistication and expertise. The agency needs an increased budget, more scientific and technical staff, and better analytical tools that support science-based decision-making and keep up with innovation in food and drug safety, and food, veterinary and medical products.

FDA’s BA (non-user fee) revenue remained essentially the same between FY 23 and FY 24, masking the challenge presented when agency resources are diminished by having to absorb pay raise increases and new initiatives without additional funding. The Alliance’s FY 25 ask covers further pay raise increases, while providing a broader view of the growing program imperatives facing the agency.

Attached to this release is the Alliance’s FY 25 ask and charts summarizing the Alliance’s FY 25 “ask” and a comparison of the President’s FY 24 and FY 25 Requests.

-------

The Alliance for a Stronger FDA is a stakeholder organization with 150+ members devoted to advocating for increased appropriations for the FDA and educating policymakers and the public about the FDA's mission and responsibilities. The Alliance’s unique coalition of patient and consumer groups and industry mirrors FDA’s unique role in public health, safety, and commerce.

Previous
Previous

The Alliance’s FY 25 Ask: Urgent Initiatives That Need More Funding

Next
Next

Next Budget Webinar on Monday; Hill Days in May